John M Wentworth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4883853/publications.pdf

Version: 2024-02-01

76 papers 3,766 citations

28 h-index 59 g-index

79 all docs

79 docs citations

79 times ranked 6622 citing authors

#	Article	IF	CITATIONS
1	A Long-Term Evaluation of Facebook for Recruitment and Retention in the ENDIA Type 1 Diabetes Pregnancy-Birth Cohort Study. Journal of Diabetes Science and Technology, 2023, 17, 696-704.	1.3	2
2	HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants. Diabetologia, 2022, 65, 88-100.	2.9	2
3	Cytotoxicity-Related Gene Expression and Chromatin Accessibility Define a Subset of CD4+ T Cells That Mark Progression to Type 1 Diabetes. Diabetes, 2022, 71, 566-577.	0.3	2
4	Characterising the age-dependent effects of risk factors on type 1 diabetes progression. Diabetologia, 2022, 65, 684.	2.9	11
5	Women with type 1 diabetes exhibit a progressive increase in gut Saccharomyces cerevisiae in pregnancy associated with evidence of gut inflammation. Diabetes Research and Clinical Practice, 2022, 184, 109189.	1.1	6
6	Mental Health During Late Pregnancy and Postpartum in Mothers With and Without Type 1 Diabetes: The ENDIA Study. Diabetes Care, 2022, 45, 1082-1090.	4.3	2
7	Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes, 2022, 71, 610-623.	0.3	59
8	Factors that predict glycaemic response to sodiumâ€glucose linked transporter (SGLT) inhibitors. Internal Medicine Journal, 2021, 51, 515-519.	0.5	1
9	Validation in the general population of a C-peptide estimate equation to measure beta cell function in recent-onset type 1 diabetes. Acta Diabetologica, 2021, 58, 115-117.	1.2	1
10	Associations between diet, the gut microbiome and short chain fatty acids in youth with islet autoimmunity and type 1 diabetes. Pediatric Diabetes, 2021, 22, 425-433.	1.2	5
11	Evaluation of protocol amendments to the Environmental Determinants of Islet Autoimmunity (ENDIA) study during the COVIDâ€19 pandemic. Diabetic Medicine, 2021, 38, e14638.	1.2	2
12	Type 1 diabetes in pregnancy is associated with distinct changes in the composition and function of the gut microbiome. Microbiome, 2021, 9, 167.	4.9	23
13	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia, 2021, 64, 2432-2444.	2.9	8
14	Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 502-514.	5.5	53
15	Pancreas size and exocrine function is decreased in young children with recentâ€onset Type 1 diabetes. Diabetic Medicine, 2020, 37, 1340-1343.	1.2	18
16	Prevention of Autoimmune Disease: The Type 1 Diabetes Paradigm. , 2020, , 1391-1413.		0
17	The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia, 2020, 63, 588-596.	2.9	58
18	Higher frequency of vertebrateâ€infecting viruses in the gut of infants born to mothers with type 1 diabetes. Pediatric Diabetes, 2020, 21, 271-279.	1.2	10

#	Article	IF	CITATIONS
19	MON-270 Diagnostic Value of Copeptin in Central Diabetes Insipidus. Journal of the Endocrine Society, 2020, 4, .	0.1	O
20	Glycaemic trajectory and predictors of suboptimal glycaemic control in people with type 2 diabetes. Internal Medicine Journal, 2020, 50, 1415-1418.	0.5	1
21	A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes. Metabolism Open, 2020, 5, 100021.	1.4	1
22	The methionine aminopeptidase 2 inhibitor ZGNâ€1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1215-1219.	2,2	8
23	Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia, 2020, 63, 885-886.	2.9	3
24	Changes in pancreatic exocrine function in young atâ€risk children followed to islet autoimmunity and type 1 diabetes in the <scp>ENDIA</scp> study. Pediatric Diabetes, 2020, 21, 945-949.	1.2	9
25	Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study. Pediatric Diabetes, 2019, 20, 574-583.	1.2	86
26	Distinct Gut Virome Profile of Pregnant Women With Type 1 Diabetes in the ENDIA Study. Open Forum Infectious Diseases, 2019, 6, ofz025.	0.4	32
27	Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables. Diabetologia, 2019, 62, 33-40.	2.9	22
28	Influence of fecal collection conditions and 16S rRNA gene sequencing at two centers on human gut microbiota analysis. Scientific Reports, 2018, 8, 4386.	1.6	46
29	Diabetes Outcomes More than a Decade Following Sustained Weight Loss After Laparoscopic Adjustable Gastric Band Surgery. Obesity Surgery, 2018, 28, 982-989.	1.1	9
30	<i>TCF7L2</i> Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care, 2018, 41, 311-317.	4.3	51
31	CD52 inhibits Toll-like receptor activation of NF-κB and triggers apoptosis to suppress inflammation. Cell Death and Differentiation, 2018, 25, 392-405.	5.0	42
32	Detailed Description of Change in Serum Cholesterol Profile with Incremental Weight Loss After Restrictive Bariatric Surgery. Obesity Surgery, 2018, 28, 1351-1362.	1.1	6
33	Proinsulin C-peptide is an autoantigen in people with type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115 , $10732-10737$.	3.3	47
34	Transcription Factor 7-Like 2 (<i>TCF7L2</i>) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care, 2018, 41, 2480-2486.	4.3	23
35	Minimal variation of the plasma lipidome after delayed processing of neonatal cord blood. Metabolomics, 2018, 14, 130.	1.4	1
36	Cord Blood CD8+ T Cells Have a Natural Propensity to Express IL-4 in a Fatty Acid Metabolism and Caspase Activation-Dependent Manner. Frontiers in Immunology, 2018, 9, 879.	2.2	11

#	Article	IF	Citations
37	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care, 2018, 41, 1887-1894.	4.3	104
38	Gut Microbiome Dysbiosis and Increased Intestinal Permeability in Australian Children with Islet Autoimmunity and Type 1 Diabetes. Diabetes, 2018, 67 , .	0.3	3
39	Solitary pituitary metastasis from <scp>HER2</scp> â€positive breast cancer. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e181-e184.	0.7	16
40	Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. Obesity Surgery, 2017, 27, 115-125.	1.1	30
41	Five-Year Outcomes of a Randomized Trial of Gastric Band Surgery in Overweight but Not Obese People With Type 2 Diabetes. Diabetes Care, 2017, 40, e44-e45.	4.3	23
42	Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S Journal of Diabetes and Its Complications, 2017, 31, 1139-1144.	1.2	10
43	Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2873-2880.	1.8	20
44	Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease. Obesity Surgery, 2017, 27, 1533-1542.	1.1	29
45	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. Diabetes Care, 2017, 40, 1494-1499.	4.3	28
46	Interferon-gamma released from omental adipose tissue of insulin-resistant humans alters adipocyte phenotype and impairs response to insulin and adiponectin release. International Journal of Obesity, 2017, 41, 1782-1789.	1.6	26
47	Type 1 diabetes: a disease of developmental origins. Pediatric Diabetes, 2017, 18, 417-421.	1.2	12
48	The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4596-4603.	1.8	20
49	Factors associated with insulinâ€induced weight gain in an Australian type 2 diabetes outpatient clinic. Internal Medicine Journal, 2016, 46, 834-839.	0.5	8
50	GM3 ganglioside and phosphatidylethanolamine-containing lipids are adipose tissue markers of insulin resistance in obese women. International Journal of Obesity, 2016, 40, 706-713.	1.6	28
51	The Effect of Weight Loss on Indigenous Australians with Diabetes: a study of Feasibility, Acceptability and Effectiveness of Laparoscopic Adjustable Gastric Banding. Obesity Surgery, 2016, 26, 45-53.	1.1	15
52	IL-18 Production from the NLRP1 Inflammasome Prevents Obesity and Metabolic Syndrome. Cell Metabolism, 2016, 23, 155-164.	7.2	133
53	Recent advances in type 1 diabetes. Medical Journal of Australia, 2015, 203, 290-293.	0.8	3
54	The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue–resident regulatory T cells. Nature Immunology, 2015, 16, 276-285.	7.0	442

#	Article	lF	Citations
55	Gastric Band Surgery Leads to Improved Insulin Secretion in Overweight People with Type 2 Diabetes. Obesity Surgery, 2015, 25, 2400-2407.	1.1	4
56	Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes. Diabetologia, 2014, 57, 463-468.	2.9	16
57	Prevention of Autoimmune Disease. , 2014, , 1191-1208.		0
58	Maturityâ€onset diabetes of the young type 5 in a family with diabetes and mild kidney disease diagnosed by whole exome sequencing. Internal Medicine Journal, 2014, 44, 1137-1140.	0.5	7
59	Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2014, 37, 2098-2107.	4.3	135
60	A randomised controlled trial of high dose vitamin D in recent-onset type 2 diabetes. Diabetes Research and Clinical Practice, 2014, 106, 576-582.	1.1	32
61	Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 545-552.	5.5	127
62	Obesity is associated with retinopathy and macrovascular disease in type 1 diabetes. Obesity Research and Clinical Practice, 2014, 8, e178-e182.	0.8	52
63	Antigen-Based Vaccination and Prevention of Type 1 Diabetes. Current Diabetes Reports, 2013, 13, 616-623.	1.7	36
64	GPR119 regulates genetic markers of fatty acid oxidation in cultured skeletal muscle myotubes. Molecular and Cellular Endocrinology, 2013, 365, 108-118.	1.6	18
65	Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 97, 57-62.	1.1	11
66	Pro-Inflammatory CD11c+CD206+ Adipose Tissue Macrophages Are Associated With Insulin Resistance in Human Obesity. Diabetes, 2010, 59, 1648-1656.	0.3	521
67	Reappraising the stereotypes of diabetes in the modern diabetogenic environment. Nature Reviews Endocrinology, 2009, 5, 483-489.	4.3	44
68	Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessary. Clinical Endocrinology, 2008, 68, 29-35.	1.2	33
69	Type 1 diabetes: Lessons for other autoimmune diseases?. Journal of Autoimmunity, 2008, 31, 306-310.	3.0	55
70	Does Insulin Resistance Need Resistin?. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2036-2037.	1.8	1
71	PAX8-Peroxisome Proliferator-Activated Receptor Î ³ (PPARÎ ³) Disrupts Normal PAX8 or PPARÎ ³ Transcriptional Function and Stimulates Follicular Thyroid Cell Growth. Endocrinology, 2006, 147, 367-376.	1.4	60
72	Effectiveness and side effects of thiazolidinediones for type 2Âdiabetes: realâ€life experience from a tertiary hospital. Medical Journal of Australia, 2004, 181, 536-539.	0.8	77

#	Article	IF	CITATIONS
73	Detection of the PAX8-PPARÎ ³ Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 354-357.	1.8	189
74	Arachidonic Acid Stimulates Glucose Uptake in 3T3-L1 Adipocytes by Increasing GLUT1 and GLUT4 Levels at the Plasma Membrane. Journal of Biological Chemistry, 2001, 276, 9149-9157.	1.6	94
75	A Dominant-negative Peroxisome Proliferator-activated Receptor Î ³ (PPARÎ ³) Mutant Is a Constitutive Repressor and Inhibits PPARÎ ³ -mediated Adipogenesis. Journal of Biological Chemistry, 2000, 275, 5754-5759.	1.6	249
76	Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. Nature Genetics, 1998, 19, 399-401.	9.4	378